Rep. Robert Bresnahan, Jr. Purchases Shares of Bio-Techne Co. (NASDAQ:TECH)

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of Bio-Techne Co. NASDAQ: TECH. In a filing disclosed on March 27th, the Representative disclosed that they had bought between $1,001 and $15,000 in Bio-Techne stock on February 25th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Intuit NASDAQ: INTU on 3/7/2025.
• Sold $1,001 - $15,000 in shares of Tesla NASDAQ: TSLA on 3/6/2025.
• Purchased $1,001 - $15,000 in shares of SEA NYSE: SE on 3/5/2025.
• Sold $1,001 - $15,000 in shares of Credo Technology Group NASDAQ: CRDO on 3/4/2025.
• Purchased $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 3/4/2025.
• Purchased $1,001 - $15,000 in shares of Twilio NYSE: TWLO on 3/4/2025.
• Sold $15,001 - $50,000 in shares of Alibaba Group NYSE: BABA on 3/4/2025.
• Purchased $1,001 - $15,000 in shares of Zoom Video Communications NASDAQ: ZM on 3/4/2025.
• Purchased $1,001 - $15,000 in shares of Intel NASDAQ: INTC on 3/3/2025.
• Purchased $1,001 - $15,000 in shares of Snowflake NYSE: SNOW on 3/3/2025.

Bio-Techne Price Performance

Shares of Bio-Techne stock traded up $0.71 during mid-day trading on Wednesday, reaching $58.06. 643,861 shares of the stock were exchanged, compared to its average volume of 1,569,152. The company has a market cap of $9.18 billion, a price-to-earnings ratio of 58.65, a price-to-earnings-growth ratio of 2.88 and a beta of 1.30. Bio-Techne Co. has a fifty-two week low of $56.60 and a fifty-two week high of $85.57. The company has a current ratio of 3.94, a quick ratio of 2.77 and a debt-to-equity ratio of 0.14. The firm has a 50-day simple moving average of $65.79 and a 200 day simple moving average of $71.21.

Remove Ads

Bio-Techne (NASDAQ:TECH - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The biotechnology company reported $0.35 earnings per share for the quarter, missing the consensus estimate of $0.38 by ($0.03). Bio-Techne had a return on equity of 12.73% and a net margin of 13.22%. On average, sell-side analysts predict that Bio-Techne Co. will post 1.67 EPS for the current fiscal year.

Bio-Techne Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, February 28th. Stockholders of record on Monday, February 17th were issued a $0.08 dividend. This represents a $0.32 annualized dividend and a dividend yield of 0.55%. The ex-dividend date was Friday, February 14th. Bio-Techne's payout ratio is 32.32%.

Insider Buying and Selling

In other Bio-Techne news, Director Amy E. Herr sold 1,860 shares of the business's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $65.96, for a total value of $122,685.60. Following the sale, the director now owns 1,976 shares in the company, valued at approximately $130,336.96. The trade was a 48.49 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Kim Kelderman sold 13,392 shares of the firm's stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $77.29, for a total transaction of $1,035,067.68. Following the transaction, the chief executive officer now directly owns 39,004 shares of the company's stock, valued at $3,014,619.16. This represents a 25.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 3.90% of the company's stock.

Institutional Investors Weigh In On Bio-Techne

Several large investors have recently bought and sold shares of TECH. California State Teachers Retirement System grew its stake in Bio-Techne by 4.0% in the fourth quarter. California State Teachers Retirement System now owns 249,350 shares of the biotechnology company's stock valued at $17,961,000 after acquiring an additional 9,625 shares during the period. Lansforsakringar Fondforvaltning AB publ bought a new stake in shares of Bio-Techne during the fourth quarter worth $3,661,000. Siemens Fonds Invest GmbH acquired a new stake in shares of Bio-Techne during the fourth quarter worth $312,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Bio-Techne during the fourth quarter worth $4,082,000. Finally, Jefferies Financial Group Inc. lifted its position in Bio-Techne by 284.6% in the 4th quarter. Jefferies Financial Group Inc. now owns 52,244 shares of the biotechnology company's stock valued at $3,763,000 after acquiring an additional 38,661 shares in the last quarter. Institutional investors own 98.95% of the company's stock.

Analysts Set New Price Targets

Several brokerages have issued reports on TECH. Evercore ISI started coverage on Bio-Techne in a research note on Tuesday, March 18th. They issued an "outperform" rating and a $75.00 price objective on the stock. Scotiabank upped their price target on shares of Bio-Techne from $88.00 to $90.00 and gave the stock a "sector outperform" rating in a research report on Thursday, February 6th. Robert W. Baird lowered shares of Bio-Techne from an "outperform" rating to a "neutral" rating and decreased their price objective for the stock from $88.00 to $68.00 in a report on Wednesday, February 19th. Royal Bank of Canada boosted their target price on shares of Bio-Techne from $79.00 to $80.00 and gave the stock a "sector perform" rating in a research note on Thursday, February 6th. Finally, Baird R W lowered Bio-Techne from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 19th. Five analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $81.25.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.